A Study on the Application and Use of Artificial Intelligence to Support Drug Development

被引:53
|
作者
Lamberti, Mary Jo [1 ]
Wilkinson, Michael [1 ]
Donzanti, Bruce A. [2 ]
Wohlhieter, G. Erich [3 ]
Parikh, Sudip [4 ]
Wilkins, Robert G. [5 ]
Getz, Ken [1 ]
机构
[1] Tufts Univ, Sch Med, Tufts Ctr Study Drug Dev, Boston, MA 02111 USA
[2] Genentech Inc, Global Pharmacovigilance Innovat Policy, San Francisco, CA 94080 USA
[3] Amgen Inc, Digital Hlth & Innovat, Thousand Oaks, CA USA
[4] Drug Informat Assoc Amer, Washington, DC USA
[5] QPS Consulting LLC, Ashburn, VA USA
关键词
AI; artificial intelligence; drug development; machine learning; technology;
D O I
10.1016/j.clinthera.2019.05.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: The Tufts Center for the Study of Drug Development (CSDD) and the Drug Information Association (DIA) in collaboration with 8 pharmaceutical and biotechnology companies conducted a study examining the adoption and effect of artificial intelligence (AI), such as machine learning, on drug development. The study was conducted to clarify and understand AI adoption across the industry and to gather detailed insights into the spectrum of activities included in the definition of AI. The study investigated and identified analytical platforms and innovations across pharmaceutical and biotechnology companies currently being used or planned for in the future. Methods: A 2-part method was used that comprised in-depth interviews with AI industry experts and a global survey conducted across pharmaceutical and biotechnology organizations. Eleven in-depth interviews focused on use and implementation of AI across drug development. The survey assessed use of AI and included perceptions about current and future use. The survey also examined technology definitions, assessment of organizational and personal AI expertise, and use of partnerships. A total of 402 responses, including data from 217 unique organizations, were analyzed. Findings: Although 7 in 10 respondents reported using AI in some capacity, a wide range of use was reported by AI type. Patient selection and recruitment for clinical studies was the most commonly reported AI activity, with 34 respondents currently using AI for this activity. In addition, identification of medicinal products data gathering was the top activity being piloted or in the planning stages, reported by 49 respondents. The study also revealed that the most significant challenges to AI implementation included staff skills (55%), data structure (52%), and budgets (49%). Nearly 60% of respondents noted planned increases in staff within 1-2 years to support AI use or implementation. Implications: Despite the challenges to AI implementation, the survey revealed that most organizations use AI in some capacity and that it is important to the success of an organization's workforce. Many organizations reported expectations for increasing staff as implementation of AI expands. Further research should examine the changing development landscape as the role of AI evolves. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:1414 / 1426
页数:13
相关论文
共 50 条
  • [41] Application of Artificial Intelligence in the Study of Fishing Vessel Behavior
    Cheng, Xin
    Zhang, Fan
    Chen, Xinjun
    Wang, Jintao
    FISHES, 2023, 8 (10)
  • [42] Artificial Intelligence in Surveillance, Diagnosis, Drug Discovery and Vaccine Development against COVID-19
    Arora, Gunjan
    Joshi, Jayadev
    Mandal, Rahul Shubhra
    Shrivastava, Nitisha
    Virmani, Richa
    Sethi, Tavpritesh
    PATHOGENS, 2021, 10 (08):
  • [43] The Role of Artificial Intelligence in Drug Discovery and Pharmaceutical Development: A Paradigm Shift in the History of Pharmaceutical Industries
    Nithin Vidiyala
    Pavani Sunkishala
    Prashanth Parupathi
    Dinesh Nyavanandi
    AAPS PharmSciTech, 26 (5)
  • [44] Environmentally sustainable development and use of artificial intelligence in health care
    Richie, Cristina
    BIOETHICS, 2022, 36 (05) : 547 - 555
  • [45] Consumer Perspectives on the Use of Artificial Intelligence Technology and Automation in Crisis Support Services: Mixed Methods Study
    Ma, Jennifer S.
    O'Riordan, Megan
    Mazzer, Kelly
    Batterham, Philip J.
    Bradford, Sally
    Kolves, Kairi
    Titov, Nickolai
    Klein, Britt
    Rickwood, Debra J.
    JMIR HUMAN FACTORS, 2022, 9 (03):
  • [46] Artificial Intelligence-Based Methods for Drug Repurposing and Development in Cancer
    Herraiz-Gil, Sara
    Nygren-Jimenez, Elisa
    Acosta-Alonso, Diana N.
    Leon, Carlos
    Guerrero-Aspizua, Sara
    APPLIED SCIENCES-BASEL, 2025, 15 (05):
  • [47] Artificial intelligence-driven drug development against autoimmune diseases
    Moingeon, Philippe
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2023, 44 (07) : 411 - 424
  • [48] Comprehensive applications of the artificial intelligence technology in new drug research and development
    Chen, Hongyu
    Lu, Dong
    Xiao, Ziyi
    Li, Shensuo
    Zhang, Wen
    Luan, Xin
    Zhang, Weidong
    Zheng, Guangyong
    HEALTH INFORMATION SCIENCE AND SYSTEMS, 2024, 12 (01):
  • [49] Use of Artificial Intelligence in Leadership Competency Development and Selection: An Empirical Study
    Bronkhorst, Pieter Viljoen
    Becker, Jurgen
    CONSULTING PSYCHOLOGY JOURNAL-PRACTICE AND RESEARCH, 2024,
  • [50] The emerging roles of artificial intelligence in cancer drug development and precision therapy
    Liang, Guosheng
    Fan, Wenguo
    Luo, Hui
    Zhu, Xiao
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 128